Evidence map›Paper›PMID 37247035›Full record

ArticleActa neurochirurgica2023

Embolization of the middle meningeal artery vs. second surgery-treatment response and volume course of recurrent chronic subdural hematomas.

Adrian Liebert, Heinz Voit-Höhne, Leonard Ritter, Thomas Eibl, Alexander Hammer, Michael Städt, Florian Eff, Markus Holtmannspötter, Hans-Herbert Steiner

Abstract read
In one paragraph

Article in Acta neurochirurgica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Rescue management of recurrent or growing non-acute subdural hematoma following standalone or adjunctive middle meningeal artery embolization: A case series and systematic review.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2025
    Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adrian LiebertDepartment of Neurosurgery, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany. adrian.liebert@stud.pmu.ac.at.ORCID 0000-0003-4798-3369
Heinz Voit-HöhneDepartment of Neuroradiology, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany.
Leonard RitterDepartment of Neurosurgery, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany.
Thomas EiblDepartment of Neurosurgery, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany.
Alexander HammerDepartment of Neurosurgery, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany.
Michael StädtDepartment of Neuroradiology, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany.
Florian EffDepartment of Neuroradiology, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany.
Markus HoltmannspötterDepartment of Neuroradiology, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany.
Hans-Herbert SteinerDepartment of Neurosurgery, Paracelsus Medical University, Breslauer Straße 201, 90471, Nuremberg, Bavaria, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite multiple studies on the embolization of the middle meningeal artery, there is limited data on the treatment response of recurrent chronic subdural hematomas (CSDH) to embolization and on the volume change.

methodsWe retrospectively compared the treatment response and volume change of recurrent CSDHs in a conventional group (second surgery) with an embolization group (embolization as stand-alone treatment) during the time-period from August 2019 until June 2022. Different clinical and radiological factors were assessed. Treatment failure was defined as necessity of treatment for second recurrence. Hematoma volumes were determined in the initial CT scan before first surgery, after the first surgery, before retreatment as well as in an early (1 day-2 weeks) and in a late follow-up CT scan (2-8 weeks).

resultsFifty recurrent hematomas after initial surgery were treated either by second surgery (n = 27) or by embolization (n = 23). 8/27 (26,6%) surgically treated and 3/23 (13%) of the hematomas treated by embolization needed to be treated again. This leads to an efficacy in recurrent hematomas of 73,4% in surgically treated and of 87% in embolized hematomas (p = 0.189). In the conventional group, mean volume decreased significantly already in the first follow-up CT scan from 101.7 ml (SD 53.7) to 60.7 ml (SD 40.3) (p = 0.001) and dropped further in the later follow-up scan to 46.6 ml (SD 37.1) (p = 0.001). In the embolization group, the mean volume did decrease insignificantly from 75.1 ml (SD 27.3) to 68 ml (SD 31.4) in the first scan (p = 0.062). However, in the late scan significant volume reduction to 30.8 ml (SD 17.1) could be observed (p = 0.002).

conclusionsEmbolization of the middle meningeal artery is an effective treatment option for recurrent CSDH. Patients with mild symptoms who can tolerate slow volume reduction are suitable for embolization, whereas patients with severe symptoms should be reserved for surgery.

Indexed as

Embolization, TherapeuticHematoma, Subdural, ChronicHumansMeningeal ArteriesRetrospective StudiesTreatment OutcomeChronic subdural hematomaEmbolizationRecurrenceTreatment responseVolume

Identifiers

PMID37247035
PMCPMC10319706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.